Sinovac Biotech, P/E Ratio

Sinovac Biotech, (SVA) currently reports a P/E ratio of -7.8. That is below the Healthcare sector average of 25.75. Use the charts on this page to explore Sinovac Biotech,'s P/E ratio history and peer comparisons.

Sinovac Biotech,'s P/E ratio of -7.8 is lower than the Healthcare sector average of 25.75. That is roughly 130.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Sinovac Biotech,'s market price to a fundamental measure such as earnings, sales, or book value. At -7.8, SVA can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -7.8, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.75. From there, open related valuation or income-statement pages for Sinovac Biotech,, and consider following SVA for alerts when major investors trade the stock.

Sinovac Biotech, is classified in the Healthcare sector. On P/E ratio, it currently shows -7.8 versus a sector average near 25.75. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SVA with unrelated industries.